MedPath

CD40L Antagonism in Rheumatoid Arthritis (RA)

Phase 2
Active, not recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo for VIB4920
Drug: VIB4920 with TNFi
Drug: VIB4920 without TNFi
Registration Number
NCT05306353
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.

Detailed Description

This study is a phase 2, multi-site, prospective, randomized, placebo-controlled, three-arm \[two arms double-blinded, one arm evaluator-blinded (participant is aware of his/her treatment status, but evaluator is not)\] trial of VIB4920 in 104 adults with seropositive Rheumatoid arthritis (RA) in the United States. Individuals will be eligible if they have moderate or high disease activity (Simplified Disease Activity Index \[SDAI\] ≥ 17) despite treatment with a TNFi, defined for this study as etanercept or adalimumab or their respective biosimilars, for at least 12 weeks.

Study participation is divided into two phases: the study drug administration period (from week 0 to week 12) and the post-administration observation period (from week 12 to week 40).

Participants will be randomized into one of the three study arms to assess safety and efficacy; VIB4920 plus TNFI (double-blinded); VIB4920 plus placebo (double-blinded); and continued TNFi treatment (evaluator-blinded).

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
104
Inclusion Criteria

  1. Participant or legally authorized representative must be able to understand and provide informed consent

  2. Adult 18-75 years of age

  3. Diagnosed with RA by fulfilling the ACR/EULAR 2010 Classification Criteria for RA ≥ 6 months prior to screening (Appendix 9)

  4. Documented positive test for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (ACPA)

  5. SDAI ≥ 17

  6. At least 4 tender and 4 swollen joints by a 44 joint count (Appendix 5)

  7. On one of the followingTNFi therapy regimens:

    1. Etanercept 50 mg SC (or its respective biosimilar) weekly for at least 12 weeks, with or without methotrexate
    2. Adalimumab 40 mg SC (or its respective biosimilar) every other week for at least 12 weeks, with or without methotrexate
    3. Adalimumab 40 mg SC weekly (or its respective biosimilar) for at least 12 weeks, without methotrexate

  8. Willing to continue or discontinue treatment with their current TNFi at the same dose depending upon study arm assignment

  9. If treated with leflunomide, sulfasalazine, or hydroxychloroquine, must be taking a stable dose for at least 12 weeks

  10. If treated with methotrexate, must be taking a stable dose for at least 12 weeks. The following exceptions are permitted within the 12 weeks prior to screening:

    1. Holding methotrexate after COVID-19 vaccination as per American College of Rheumatology guidance (https://rheumatology.org/)
    2. Holding methotrexate for 1 or 2 weeks after influenza vaccination

  11. COVID-19 vaccination according to the current Centers for Disease Control and Prevention (CDC) vaccination recommendations for individuals who are moderately to severely immunocompromised, with the last COVID-19 vaccine dose administered at least 14 days prior to the initiation of the study drug (Visit 0)

  12. All participants who engage in sexual activity that could lead to pregnancy must agree to use abstinence or an FDA-approved contraception for the duration of the study to prevent pregnancy (Section 7.5)

Read More
Exclusion Criteria

  1. Inability or unwillingness to give written informed consent or comply with the study protocol

  2. Prior or ongoing systemic inflammatory or autoimmune disease (other than RA and secondary Sjögren's syndrome) requiring or potentially requiring other systemic immunomodulatory therapy during the 40-week study period

  3. Use of glucocorticoid and/or disease-modifying therapies as specified below:

    1. Prior treatment with any B cell depleting therapy (e.g., rituximab)
    2. History of treatment with more than two different TNFi, including the current treatment with etanercept, adalimumab, or their respective biosimilars. Treatment with a brand name TNFi (e.g., Enbrel or Humira) and its respective biosimilar would count as a single TNFi if treatment has been continuous and without interruption by more than 90 days when switching between the brand name and biosimilar TNFi.
    3. Treatment with other biologic therapy (i.e., not targeting TNF-α), including abatacept, tocilizumab, or sarilumab within the previous 12 weeks
    4. Treatment with a JAK inhibitor within the previous 12 weeks
    5. Concurrent use of methotrexate and leflunomide in combination
    6. Prednisone > 10 mg a day or equivalent glucocorticoid use within the previous 4 weeks
    7. Intramuscular, intra-articular, or intravenous glucocorticoids within the previous 4 weeks
    8. Other immunomodulatory medications within the previous 12 weeks except for methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine

  4. Lack of any subjective or objective clinical response (i.e., complete non-responder) to current TNFi use, in the opinion of the study investigator based on information provided by the patient and referring rheumatologist

  5. Use of an investigational agent including VIB4920 in the past 30 days or 5 half-lives, whichever is longer

  6. History of a severe allergy, hypersensitivity reaction, or infusion reaction to any component of the VIB4920 formulation

  7. History of Felty's syndrome

  8. History of interstitial lung disease with FVC < 70% predicted, DLCO < 70% predicted, or requiring supplemental oxygen

  9. Deep venous thrombosis or thromboembolism including pulmonary embolism in the prior two years

  10. Infection:

    a. Evidence of current or prior infection with hepatitis B, as indicated by a positive test for the hepatitis B surface antigen (HBsAg) or a positive test for the hepatitis B core antibody (HBcAb) b. Positive HCV serology unless treated with an anti-viral regimen resulting in a sustained virologic response (undetectable viral load 24 weeks after cessation of therapy) c. Evidence of HIV infection d. Evidence of active tuberculosis, untreated or incompletely treated latent tuberculosis, or recent close contact with a person who has active tuberculosis e. Positive QuantiFERON-TB Gold, QuantiFERON-TB Gold Plus, or T-SPOT-TB test without history of previous treatment for active or latent TB f. Indeterminate QuantiFERON-TB Gold, QuantiFERON-TB Gold Plus, or T-SPOT.TB test which remains indeterminate on repeat testing, and any of the following additional required screening which indicates an increased risk of TB infection: i. History of tuberculosis exposure ii. History of travel to an area where tuberculosis is endemic iii. Findings on chest radiograph suggestive of prior exposure to tuberculosis (e.g., granulomas or apical scarring) obtained at screening or within the past 3 months iv. Positive purified protein derivative (PPD) skin test for tuberculosis obtained in the past 3 months, either obtained at screening or within the past 3 months v. Prior history of a positive QuantiFERON-TB Gold, QuantiFERON-TB Gold Plus, T-SPOT.TB, or purified protein derivative (PPD) test without history of previous treatment for latent TB g. Positive test for acute SARS-CoV-2 infection (e.g., PCR test for SARS-CoV-2 or alternative viral test according to CDC guidance) h. Symptoms of presumed or documented SARS-CoV-2 infection in the past 30 days i. More than one episode of herpes zoster in the past 12 months

    j. An opportunistic infection in the past 12 months k. Acute or chronic infection, including current use of suppressive systemic anti-microbial therapy for chronic or recurrent bacterial or fungal infection, hospitalization for treatment of infection in the past 60 days, or parenteral anti-microbial (including anti-bacterial, anti-viral, or anti-fungal agents) use in the past 60 days for infection l. History of bronchiectasis with recurrent pulmonary infections

  11. History of a primary immunodeficiency disorder

  12. Vaccination with a live vaccine within the past 30 days

  13. Women who are pregnant or breast-feeding

  14. WBC count < 3.0 x 103/μl

  15. Absolute neutrophil count < 1.5 x 103/μl

  16. Hemoglobin < 9 g/dL

  17. Platelet count < 100 x 103/μl

  18. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal (ULN)

  19. History of malignant neoplasm within the last 5 years, except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally

  20. Current, diagnosed mental illness or current, diagnosed or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements

  21. Any new or uncontrolled condition occurring within the past 12 weeks which, in the judgment of the investigator, could interfere with participation in the trial (e.g., diabetes mellitus with HbA1c ≥ 9.0%, myocardial infarction, or stroke)

  22. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study

  23. Inability to comply with study and follow-up procedures

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VIB4920 Placebo with TNFiPlacebo for VIB4920Participants will receive VIB4920 placebo in a blinded fashion intravenously at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period VIB4920 placebo consists of 0.9% normal saline in 250mL bags.
VIB4920 with TNFiVIB4920 with TNFiParticipants will receive VIB4920 in a blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period
VIB4920 without TNFiVIB4920 without TNFiParticipants will stop TNFi after randomization to this arm, and receive VIB4920 in an evaluator-blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 while maintaining all other background disease-modifying RA therapy (e.g., methotrexate, hydroxychloroquine, etc.) through the study period. This arm is evaluator blinded (not aware of treatment status), with the participant aware of treatment status but evaluator is not, due to not using a TNFi placebo for this study
Primary Outcome Measures
NameTimeMethod
Proportion of participants achieving low disease activity by Simplified Disease Activity Index (SDAI)Week 16

Defined by a Simplified Disease Activity Index (SDAI) \<= 11

Participants who escalate their disease-modifying therapy or take any prohibited medications for treatment of RA prior to Week 16 are considered to have failed the primary endpoint. The primary analysis will compare the primary endpoint between the two blinded study arms: VIB4920 with TNFi and VIB4920 placebo with TNFi study arms

Secondary Outcome Measures
NameTimeMethod
The proportion of participants achieving an ACR 70 responseWeek 40
Time to loss of low disease activity defined by SDAIWeek 16

Defined by Simplified Disease Activity Index (SDAI) \> 11 for the subset of individuals achieving low disease activity by the SDAI criteria. Participants who escalate their disease-modifying therapy or take prohibited medications for treatment of their RA will be considered to have lost the low disease activity or remission response

Time to loss of low disease activity defined by DAS28-CRPWeek 16

Defined by Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP) \> 3.2 for the subset of individuals achieving low disease activity by the DAS28-CRP criteria. Participants who escalate their disease-modifying therapy or take prohibited medications for treatment of their RA will be considered to have lost the low disease activity or remission response

Time to loss of remission defined by SDAIWeek 16

Defined by Simplified Disease Activity Index (SDAI) \> 3.3 for the subset of individuals achieving remission by the SDAI criteria. Participants who escalate their disease-modifying therapy or take prohibited medications for treatment of their RA will be considered to have lost the low disease activity or remission response

Time to loss of remission defined by DAS28-CRPWeek 16

Defined by DAS28-CRP \>= 2.6 for the subset of individuals achieving remission by the DAS28-CRP criteria. Participants who escalate their disease-modifying therapy or take prohibited medications for treatment of their RA will be considered to have lost the low disease activity or remission response

Longitudinal trends in Simplified Disease Activity Index (SDAI)Week 0 to Week 40
Longitudinal trends in Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP)Week 0 to Week 40
Change in the Health Assessment Questionnaire - Disability Index (HAQ-DI)Week 0 to 40
Change in Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) Profile scoresWeek 0 to 16
Incidence of grade 2 or higher adverse events (AEs)Week 0 to Week 40

Liver chemistry abnormalities will be graded using protocol specific criteria, defined relative to the upper limit of normal (ULN):

* Aspartate aminotransferase \[AST\] increased: Grade 2: \> 3.0x ULN - 5.0x ULN, Grade 3: \> 5.0x ULN - 20.0x ULN, Grade 4: \> 20.0x ULN

* Alanine aminotransferase \[ALT\] increased: Grade 2: \> 3.0x ULN - 5.0x ULN, Grade 3: \> 5.0x ULN - 20.0x ULN, Grade 4: \> 20.0x ULN

* Alkaline phosphatase \[ALP\] increased: Grade 2: \> 2.5x ULN - 5.0x ULN, Grade 3: \> 5.0x ULN - 20.0x ULN, Grade 4: \> 20.0x ULN

* Blood bilirubin increased: Grade 2: \> 1.5x ULN - 3.0x ULN, Grade 3: \> 3.0x ULN - 10.0x ULN, Grade 4: \> 10.0x ULN

All other AEs will be graded according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Incidence of serious adverse eventsWeek 0 to Week 40

An adverse event or suspected adverse reaction is considered "serious" if, in the view of either the investigator or Sponsor (DAIT/NIAID), it results in any of the following outcomes (21 CFR 312.32(a)):

1. Death.

2. A life-threatening event: An AE or SAR is considered "life-threatening" if, in the view of either the investigator or Sponsor (DAIT/NIAID), its occurrence places the participant at immediate risk of death. It does not include an AE or SAR that, had it occurred in a more severe form, might have caused death.

3. Inpatient hospitalization or prolongation of existing hospitalization.

4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.

5. Congenital anomaly or birth defect.

The proportion of participants achieving an ACR50 responseWeek 40
Proportion of participants who achieve sustained remissionWeek 16 to Week 40

Defined by Simplified Disease Activity Index (SDAI) \<= 3.3

Proportion of participants achieving remission defined by SDAIWeek 16

Defined by Simplified Disease Activity Index (SDAI) \<= 3.3. Participants who escalate their disease-modifying therapy or take prohibited medications for treatment of their RA prior to week 16 are considered to have failed this secondary endpoint

Incidence of adverse events of special interest (AESI)Week 0 to Week 40

The following are considered Adverse Events of Special Interest (AESI):

* Anaphylaxis and grade 3 or higher hypersensitivity reactions

* Grade 3 or higher infusion reactions

* AST or ALT \>3xULN with serum total bilirubin \> 2xULN (Hy's Law)

* Grade 3 or higher infection

* Opportunistic infections including but not limited to reactivation of latent viral infections, invasive fungal infections, and TB

* Malignant neoplasm

* Immune complex disease

The proportion of participants achieving an ACR70 responseWeek 16
Proportion of participants achieving low disease activity by Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP)Week 16

Defined by Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP) \<= 3.2

Proportion of participants achieving remission defined by DAS28-CRPWeek 16

Defined by Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP) \< 2.6. Participants who escalate their disease-modifying therapy or take prohibited medications for treatment of their Rheumatoid Arthritis (RA) prior to week 16 are considered to have failed this secondary endpoint

The proportion of participants achieving an ACR20 responseWeek 40
Time to first occurrence of low disease activity as defined by SDAIWeek 0 to Week 40

Defined by SDAI \<= 11; for participants who fail to achieve low disease activity or remission prior to escalating their disease-modifying therapy or taking a prohibited medication for treatment of RA, we will assume low disease activity and remission is not achievable.

Time to first occurrence of low disease activity as defined by DAS28-CRPWeek 0 to Week 40

Defined by Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP) \<= 3.2; for participants who fail to achieve low disease activity or remission prior to escalating their disease-modifying therapy or taking a prohibited medication for treatment of RA, we will assume low disease activity and remission is not achievable.

Time to first occurrence of remission as defined by SDAIWeek 0 to Week 40

Defined by Simplified Disease Activity Index (SDAI) \<= 3.3; for participants who fail to achieve low disease activity or remission prior to escalating their disease-modifying therapy or taking a prohibited medication for treatment of RA, we will assume low disease activity and remission is not achievable.

Time to first occurrence of remission as defined by DAS28-CRPWeek 0 to Week 40

Defined by Disease Activity Score-28 for Rheumatoid Arthritis with CRP (DAS28-CRP) \< 2.6; for participants who fail to achieve low disease activity or remission prior to escalating their disease-modifying therapy or taking a prohibited medication for treatment of RA, we will assume low disease activity and remission is not achievable.

Trial Locations

Locations (5)

University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center

🇺🇸

San Francisco, California, United States

University of Colorado School of Medicine: Division of Rheumatology

🇺🇸

Aurora, Colorado, United States

Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology

🇺🇸

Boston, Massachusetts, United States

University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology

🇺🇸

Ann Arbor, Michigan, United States

Duke University Medical Center: Division of Rheumatology and Immunology

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy